ACRO BIOMEDICAL CO., LTD.
acrobiomedicalco.comACRO Biomedical Co Ltd (OTC: ACBM) is a development-stage biomedical company pursuing the development and commercialization of cordyceps-infused animal feed products, specifically a cordyceps-infused chicken feed. The company has not demonstrated an ability to generate gross profit sufficient to sustain operations, as disclosed in its 10-K filed February 11, 2026. Revenue, if any, is expected to come from transactional product sales to chicken farmers and animal feed distributors. Prior end-user markets were concentrated in China and Hong Kong, per the same filing. The common stock trades on the OTC Markets Expert Market, where market makers cannot quote prices, and the most recent reported trade was $0.0007 as of June 30, 2025. The company requires significant external funding to develop and implement its business plan and has not yet secured distribution agreements or regulatory approvals necessary to market its proposed products.
Products & Services
Cordyceps-infused chicken feed (proposed, not yet commercially launched as of the 10-K filed 2026-02-11).
Revenue Model
Transactional product sales of cordyceps-infused chicken feed to chicken farmers and animal feed distributors, as described in the 10-K filed 2026-02-11. No revenue model is currently operational; the company is in a development stage.
Customers & Markets
Chicken farmers and animal feed distributors as direct customers; prior end-user markets concentrated in China and Hong Kong, per 10-K filed 2026-02-11.
Geographic Exposure
Prior end-user sales in China and Hong Kong; prospective U.S. market development noted as uncertain in 10-K filed 2026-02-11.
Financial snapshot data is not available right now.
Loading...
